What's Next for Geron and Imetelstat?

A closer look at the promise and peril of Geron's imetelstat and the author's expectation of the most likely outcome from its current clinical hold.

Mar 19, 2014 at 12:05PM

It's been a volatile year for clinical-stage cancer-focused biopharmaceutical company Geron (NASDAQ:GERN), whose shares moved lower by 60% last week following the announcement of a full clinical hold of its only clinical compound, imetelstat, and rocketed higher by nearly 40% yesterday despite a lack of company-specific news.

There's a lot of promise and plenty of potential for failure built into imetelstat at this point, and the opportunities and threats afforded by this potential therapy for myelofibrosis, polycythemia vera, and multiple myeloma certainly merit a closer examination.


Source: Geron.

The promise of imetelstat
Let's first look at the promise behind imetelstat and the reason why Geron shares rallied as high as $7.79 over the trailing year.

Perhaps the most intriguing aspect of imetelstat is that it offers a completely different approach than all other myelofibrosis treatments currently available or in clinical trials.

The only therapy currently approved by the Food and Drug Administration to treat myelofibrosis, a disorder where abnormal blood cells build up inside a patient's bone marrow, is Incyte (NASDAQ:INCY) and Novartis' Jakafi (known as Jakavi outside the U.S.), which is a JAK2 inhibitor. JAK2 is an enzyme that plays a key role in signal transduction; therefore, blocking JAK2 can inhibit the development cytokines that lead to cancer cell proliferation.

There are also a number of other JAK2 inhibitors currently under clinical development to treat myelofibrosis, including Cell Therapeutics' (NASDAQ:CTIC) pacritinib, which is being tested in two phase 3 trials, PERSIST-1 and PERSIST-2, which are differentiated based on a patient's platelet count, and Gilead Sciences(NASDAQ:GILD) momelotinib, which was acquired when it purchased YMI Biosciences in 2012 and is also in late-stage trials. In addition, Gilead has an in-house developed therapy, simtuzumab, also being studied in mid-stage trials as a potential myelofibrosis therapy.

The point being that JAK2 inhibitors dominate the current landscape of myelofibrosis... with the exception of imetelstat.

Geron's imetelstat is a telomerase-inhibiting therapy designed to inhibit "clonal proliferation of malignant progenitor cells compared to normal progenitors." An abstract presented at the American Society of Hematology's annual meeting in 2013, which you can view here, deemed that JAK2 mutations weren't specific or pathogenetically essential for myelofibrosis, but that telomerase inhibitors provided selective anti-clonal activity. In other words, instead of simply lessening the symptoms associated with myelofibrosis via JAK2 inhibitors, this study appears to demonstrate that telomerase inhibitors actually have the potential to treat the disease.

Source: Geron. 

The investigator-sponsored trial (IST) conducted by the Mayo Clinic would signify that imetelstat does indeed have positive cancer-fighting potential. Released in December and involving 22 patients with myelofibrosis, imetelstat produced a partial or complete remission in five patients with 41% overall responding to the therapy. This is unique because complete responses in myelofibrosis are incredibly rare.

The perils of imetelstat
On the other hand, imetelstat is still very much untested and unknown as we discovered last week when Geron announced that imetelstat had been placed on full clinical hold by the FDA.

According to the FDA, it's concerned with persistent low-grade liver function test abnormalities that showed up in its phase 2 polycythemia vera study. The hold is based on the possibility that long-term use of imetelstat could lead to liver damage, and the agency is uncertain if the low-grade liver function in current study patients is reversible.

Making matters worse for Geron, after abandoning its stem-cell research in 2011 imetelstat represents its only clinically researched drug. With imetelstat on clinical hold, Geron is akin to being afloat in the middle of the ocean without sails or paddles. The company did have $66.2 million in cash as of its most recent quarter and generated gross proceeds of $90 million with a common stock offering of 22.5 million shares in January, meaning it has plenty of cash to keep its operations going in the meantime, but its lack of pipeline depth is worrisome.

What's next for imetelstat?
At this point, there are three possible outcomes for imetelstat: complete removal of its clinical hold, removal of its clinical hold with considerably tougher warnings, or discontinuation of the study.

If I were forced to choose a possible outcome, my personal opinion is that Geron will be allowed to continue its study of imetelstat with considerably tougher standards, which may wind up excluding some patients from the treatment.

Based on limited study data thus far, and the fact that imetelstat delivered a complete response in its IST trial, something not seen with JAK2 inhibitors, it's pretty evident that it has a strong anticancer effect. But the FDA simply can't look the other way when it comes to safety. What this could mean is that imetelstat may take a backseat to JAK2 inhibitors when it comes to myelofibrosis treatment and could be used only as a last resort therapy.

I'd point to Ariad Pharmaceuticals (NASDAQ:ARIA) here, which had its FDA-approved leukemia drug Iclusig temporarily removed from pharmacy shelves in October for a few weeks after a two-year follow-up study showed an increase in severe thrombotic events (i.e., blood clots) in patients taking the drug. Thankfully for Ariad and shareholders, Iclusig was allowed to return to market just weeks later, but had additional safety warnings attached to help physicians when prescribing the drug. It also was relegated to something of a last resort treatment in its approved indications. We could see something very similar happen to imetelstat, which wouldn't be devastating, all things considered, but could rule out a quick ramp-up in revenue or a huge patient pool if approved.

What will really matter is whether current imetelstat trial patients' liver function can be stabilized and improved. There's always the possibility imetelstat could be combined with a concurrent therapy to help regulate liver function, but there's also the potential that it could be shelved completely as well due to safety concerns.

Either way, I do suggest keeping your eyes on Geron as imetelstat has demonstrated flashes of potential, and the ultimate determination by the FDA of imetelstat's safety will go a long way to determining whether Geron heads significantly higher or lower from here.

Geron and imetelstat have demonstrated tons of potential, but even they could struggle to keep pace with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers